) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2%. By the end of trading, Johnson & Johnson rose 62 cents (0.9%) to $67.56 on average volume. Throughout the day, 17.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 15.2 million shares. The stock ranged in a price between $67.22-$67.70 after having opened the day at $67.43 as compared to the previous trading day's close of $66.94. Other companies within the Drugs industry that increased today were:
), up 43.4%,
), up 28.9%,
), up 21.7%, and
), up 14.9%.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $183.57 billion and is part of the
sector. The company has a P/E ratio of 18.3, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 2.1% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and eight rate it a hold.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Johnson & Johnson Ratings Report.
On the negative front,
), down 16.1%,
), down 11.5%,
), down 11.1%, and
), down 9.1%, were all losers within the drugs industry with
) being today's drugs industry loser.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.